![]() |
市場調查報告書
商品編碼
1496835
全球 COVID-19 臨床試驗市場:依產品、階段 - 預測(2024-2030 年)COVID-19 Clinical Trials Market by Product (Therapeutics, Vaccines), Phase (Phase I, Phase II, Phase III) - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
全球COVID-19臨床試驗市場規模將於2023年達到59.5億美元,2024年達到67.9億美元,複合年成長率為13.93%,預計到2030年將達到148.4億美元。
COVID-19 臨床試驗市場包括調查各種治療方法、疫苗和藥物對抗 COVID-19 大流行的有效性和安全性的所有研究活動和試驗。 COVID-19 大流行的強度直接影響了世界各地臨床試驗的數量,加劇了有效治療方法和疫苗的緊迫性。增加政府和私人對 COVID-19 研究的資助以及加快監管進程極大地促進了市場的成長。製藥公司和研究機構之間不斷加強的全球合作正在為 COVID-19 藥物的臨床研究創造協同效應,並推動市場成長。然而,進行臨床試驗成本高昂、複雜,並且需要快速開發和核准,對資源造成巨大壓力。道德考量、病患招募和保留是可能阻礙市場成長的持續挑戰。此外,COVID-19 的持續突變為開發新的或更新的疫苗和治療方法提供了機會。更重視對抗 COVID-19 的個人化醫療策略和精準醫療可能會帶來更新的標靶治療,從而吸引市場成長機會。
主要市場統計 | |
---|---|
基準年[2023] | 59.5億美元 |
預測年份 [2024] | 67.9億美元 |
預測年份 [2030] | 148.4億美元 |
複合年成長率(%) | 13.93% |
區域洞察
在美洲,美國和加拿大消費者對 COVID-19 治療和疫苗的巨大需求透過疫苗的快速臨床試驗和緊急使用核准得到滿足。美洲的臨床試驗著重於疫苗開發和治療性介入,有助於 COVID-19 治療的快速發展。歐盟國家一致努力進行符合歐洲藥品管理局 (EMA) 嚴格規定的臨床試驗。歐盟委員會正在資助 Horizon Europe 計劃下的多項研究舉措,以推進 COVID-19 診斷和治療方法的開發。在亞太地區,中國和印度在 COVID-19 疫苗的開發和分銷方面發揮關鍵作用,對本土疫苗進行了大量臨床試驗。亞太地區各國政府正在推出一系列舉措,支持疫苗分發並使更多人能夠獲得疫苗。
FPNV定位矩陣
FPNV 定位矩陣對於評估供應商在 COVID-19 臨床試驗市場的市場定位至關重要。此矩陣提供了對供應商的全面評估,並檢驗了與業務策略和產品滿意度相關的關鍵指標。這種詳細的評估使用戶能夠根據自己的要求做出明智的決定。根據評估,供應商被分為代表其成功程度的四個像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市場佔有率分析
市場佔有率分析是一種綜合工具,可對 COVID-19 臨床試驗市場中供應商的現狀進行深入而詳細的評估。透過仔細比較和分析供應商的貢獻,您可以更深入地了解每個供應商的績效以及他們在爭奪市場佔有率時面臨的挑戰。這些貢獻包括整體收益、客戶群和其他重要指標。此外,該分析還提供了對該行業競爭力的寶貴見解,包括研究基準年期間觀察到的累積、分散主導地位和合併特徵等因素。有了這些詳細資訊,供應商可以做出更明智的決策並製定有效的策略,以在市場競爭中保持領先地位。
策略分析與建議
策略分析對於尋求在全球市場站穩腳跟的組織至關重要。對目前在 COVID-19 臨床試驗市場中的地位進行全面評估可以幫助公司做出符合其長期願望的明智決策。此關鍵評估涉及對組織的資源、能力和整體績效進行徹底分析,以確定核心優勢和需要改進的領域。
[188 Pages Report] The COVID-19 Clinical Trials Market size was estimated at USD 5.95 billion in 2023 and expected to reach USD 6.79 billion in 2024, at a CAGR 13.93% to reach USD 14.84 billion by 2030.
The COVID-19 clinical trials market comprises all research activities and trials to examine the efficacy and safety of various treatments, vaccines, and medications to combat the COVID-19 pandemic. The intensity of the COVID-19 pandemic spurred the urgency for effective treatments and vaccines, directly impacting the number of trials worldwide. The increased governmental and private funding for COVID-19 research and accelerated regulatory processes contributed significantly to the market growth. The rising global collaboration between pharmaceutical companies and research institutions creates synergies in clinical research of COVID-19 drugs, enhancing market growth. However, the high cost and complexity of conducting clinical trials and the need for rapid development and approval put considerable strain on resources. Ethical considerations, patient recruitment, and retention are constant challenges that may impede market growth. Moreover, the ongoing mutation of the coronavirus presents opportunities for developing new or updated vaccines and treatments. The growing emphasis on personalized healthcare strategies and precision medicine to combat COVID-19 can lead to newer targeted therapies, attracting opportunities for market growth.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 5.95 billion |
Estimated Year [2024] | USD 6.79 billion |
Forecast Year [2030] | USD 14.84 billion |
CAGR (%) | 13.93% |
Regional Insights
In the Americas region, significant consumer need for COVID-19 treatments and vaccines in the United States and Canada was met through swift clinical trials and emergency use authorization of vaccines. Clinical trials in the Americas region have focused on vaccine development and therapeutic interventions, contributing to the rapid development of COVID-19 therapies. Within EU countries, there has been a concerted effort to conduct clinical trials that adhere to the stringent regulations of the European Medicines Agency (EMA). The European Commission has funded several research initiatives under the Horizon Europe program to advance the development of COVID-19 diagnostics and treatments. In the APAC region, China and India have played a pivotal role in COVID-19 vaccine development and distribution, conducting numerous clinical trials for in-house developed vaccines. The governments in the APAC region have rolled out an array of initiatives to support vaccine distribution and accessibility to the broader population.
Market Insights
The market dynamics represent an ever-changing landscape of the COVID-19 Clinical Trials Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the COVID-19 Clinical Trials Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the COVID-19 Clinical Trials Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
ICON Partners with US Government for Clinical Trials of Covid-19 Vaccines
The U.S. Biomedical Advanced Research and Development Authority (BARDA), part of the nation's Strategic Preparedness and Response arm, has engaged in a critical initiative, Project NextGen, to cultivate COVID-19 vaccines and treatments responsive to prevailing and emergent strains. BARDA has partnered with ICON, a renowned firm for its prowess in clinical trial management, to assess the effectiveness of a next-generation vaccine relative to existing approvals. [Published On: 2023-09-14]
NIH Launches Clinical Trials for Long COVID Treatments
The National Institutes of Health, through its Researching COVID to Enhance Recovery (RECOVER) Initiative, has commenced enrollment for a series of nationwide clinical trials aimed at identifying effective treatments for long-term COVID-19. This groundbreaking research employs innovative platform protocols, permitting concurrent evaluation of various treatments for the management of COVID-19. The RECOVER Initiative's efforts are fundamental in understanding this complex condition and providing afflicted individuals with safe, effective therapeutic options. [Published On: 2023-08-18]
Moderna Clinical Trial Data Confirm Its Updated COVID-19 Vaccine Generates Robust Immune Response in Humans Against Widely Circulating Variants
Moderna, Inc. has disclosed encouraging preliminary results from clinical trials for its updated COVID-19 vaccine, tailored for the 2023 fall vaccination campaign. On the pathway to delivering health security globally, Moderna, Inc. has approached regulatory bodies, including the FDA and EMA, for authorization and aims to ensure ample supply is poised for the fall vaccination period upon approval. [Published On: 2023-08-17]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the COVID-19 Clinical Trials Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the COVID-19 Clinical Trials Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Bharat Biotech Ltd., BioNTech SE, Clario, GeoVax, Gilead Sciences, Inc., GlaxoSmithKline PLC, ICON PLC, Inovio Pharmaceuticals, Inc., IQVIA Inc., Johnson & Johnson Services, Inc., Laboratory Corporation of America Holdings, Medidata Solutions, Merck & Co., Inc., Moderna, Inc., Novartis AG, Novavax, Inc., Novotech, PAREXEL International Corporation, Pfizer Inc., PPD, Inc. by Thermo Fisher Scientific, Inc., Quanticate, Regeneron Pharmaceuticals, Inc., Sanofi SE, Takeda Pharmaceutical Company Limited, and Valneva SE.
Market Segmentation & Coverage